Weak association between arterial hypertension and overactive bladder baseline symptoms and treatment responses

Basit Öğe Kaydı
dc.authorid0000-0002-6308-1763
dc.contributor.authorMichel, Martin C.
dc.contributor.authorHeemann, Uwe
dc.contributor.authorde la Rosette, Jean J. M. C. H.
dc.date.accessioned2023-01-06T11:34:01Z
dc.date.available2023-01-06T11:34:01Z
dc.date.issued2022
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Üroloji Ana Bilim Dalı
dc.departmentİstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Üroloji Ana Bilim Dalı
dc.description.abstractWhile animal studies have suggested an association between the presence of hypertension and the presence and/or severity of overactive bladder syndrome (OAB) symptoms, little clinical data is available. We have conducted a pre-specified secondary analysis of a non-interventional study involving 4450 OAB patients being treated with solifenacin to explore the existence of an association between OAB and hypertension using three parallel and overlapping definitions of hypertension to enhance robustness of analysis. Regardless of definition, patients with hypertension were older and had greater OAB symptom severity in univariate analyses. In multiple regression models including age as explanatory covariate, most relationships held up but effect sizes of concomitant hypertension on OAB severity were small (odds ratios <1.35 in all cases) and were deemed to be unlikely of clinical relevance. % Changes in symptom severity were somewhat smaller in univariate analysis, but effect sizes were small. We conclude that OAB and arterial hypertension are associated but effect sizes are too small to justify adaptation of clinical practice for OAB patients with concomitant hypertension.
dc.description.sponsorshipAstellas Pharma GmbH ; Deutsche Forschungsgemeinschaften_US
dc.identifier.citationMichel, M. C., Heemann, U. ve de la Rosette, J. J. M. C. H. (2022). Weak association between arterial hypertension and overactive bladder baseline symptoms and treatment responses. Frontiers in Pharmacology, 13. https://dx.doi.org/10.3389/fphar.2022.1081074
dc.identifier.doi10.3389/fphar.2022.1081074
dc.identifier.issn1663-9812
dc.identifier.pmid36582525
dc.identifier.scopus2-s2.0-85145070462
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://dx.doi.org/10.3389/fphar.2022.1081074
dc.identifier.urihttps://hdl.handle.net/20.500.12511/10259
dc.identifier.volume13
dc.identifier.wos000904318800001en_US
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorde la Rosette, Jean J. M. C. H.
dc.language.isoen
dc.publisherFrontiers Media S.A.
dc.relation.ispartofFrontiers in Pharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution 4.0 International*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subjectOveractive Bladder Syndrome
dc.subjectArterial Hypertension
dc.subjectNon-Interventional Study
dc.subjectPathophysiology
dc.subjectSolifenacin
dc.subjectTreatment
dc.titleWeak association between arterial hypertension and overactive bladder baseline symptoms and treatment responses
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
delaRosette-Jean-2022.pdf
Boyut:
611.83 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu